Skip to main content
50°
Rain
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Pharvaris N.V.
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
March 18, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
March 06, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
March 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
February 22, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Extraordinary Meeting of Shareholders
February 16, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present at the WSAAI Annual Meeting 2024
January 26, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
January 22, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
January 05, 2024
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
December 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Pricing of $300 Million Underwritten Offering of Ordinary Shares and Pre-funded Warrants
December 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks
December 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris to Present at the GA²LEN UCARE Conference 2023
November 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer
November 15, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting
November 09, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting
October 30, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the APAAACI 2023 International Conference
October 13, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the CIIC Fall 2023 Conference
October 04, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Participate in the 2023 Cantor Global Healthcare Conference
September 19, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the 18th German Allergy Congress
September 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
September 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris To Present at the 2023 HAEi Regional Conference EMEA
August 23, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports Second Quarter 2023 Financial Results and Provides Business Update
August 07, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Presents Clinical Data at the 2023 U.S. HAEA National Summit
July 21, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE
June 26, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces $70 Million Private Placement Financing
June 20, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023
June 10, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Announces Annual Meeting of Shareholders
June 01, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Pharvaris Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Deucrictibant Data Highlighted in Multiple Presentations at the C1-Inhibitor Deficiency and Angioedema Workshop
May 06, 2023
From
Pharvaris N.V.
Via
GlobeNewswire
Tickers
PHVS
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.